对角膜新血管化局部药物治疗的最新进展
Xin-Can Huang1, Guo-Yang Xu2, Pei-Pei Yang2
1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai, 200080, China.
ChemMedChem
|October 16, 2025
概括
角膜新血管化 (CNV) 会导致失明,目前的治疗方法有限. 先进的药物输送系统显示出改善局部治疗疗效和生物可用性的承诺.
科学领域:
- 眼科医生 眼科 眼科
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
背景情况:
- 角膜新血管化 (CNV) 是一种病理状况,新血管生长到通常无血管的角膜.
- 经常由创伤或炎症引起的CNV显著影响视力,是眼科的主要挑战,失明率高达12%.
- 现有的治疗方法,如抗炎药物/抗血管原药和激光光凝,都有局限性,包括侵入性和低于最佳的疗效.
研究的目的:
- 审查角膜新血管化 (CNV) 局部药物治疗的最新进展.
- 讨论CNV的致病性,当前的治疗药物和新药输送策略.
- 突出提高眼睛表面疾病局部治疗方法的生物可用性的方法.
主要方法:
- 文献综述最近在CNV的局部药物治疗方面取得的进展.
- 对CNV的病变发生,治疗剂和输送策略的分析.
- 检查纳米技术和基于水凝的系统,以改善眼部药物输送.
主要成果:
- 传统的眼滴具有有限的生物利用率 (1-5%) 由于眼睛表面障碍,限制治疗效果.
- 包括纳米技术和水凝在内的先进的药物递送系统正在开发中,以改善药物保留,角膜透和释放.
- 这些新的系统旨在克服传统的局部治疗CNV的局限性.
结论:
- 开发有效,安全和方便的局部治疗方法对于管理CNV至关重要.
- 优化药物输送系统是提高CNV局部治疗疗效的关键.
- 最近在药物输送方面的创新表明,在患有角膜新血管化的患者中改善治疗结果的巨大潜力.
相关概念视频
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:27Open Angle Glaucoma: Treatment
958
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
958
01:25Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
01:26Drug Administration and Therapy Phases: Overview
1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457